Oxyquinoline

Oxyquinoline

SCHEMBL460412

[Ga+3].[O-]c1cccc2cccnc12.[O-]c1cccc2cccnc12.[O-]c1cccc2cccnc12

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.58
LMNA P02545 3/20 0.58
CCR1 P32246 3/20 0.58
CCR5 P51681 3/20 0.58
CCR8 P51685 3/20 0.58
MMP2 P08253 2/20 0.58
TSHR P16473 2/20 0.58
CYP3A4 P08684 2/20 0.58
MAPT P10636 2/20 0.58
ALOX15 P16050 2/20 0.58
HTT P42858 2/20 0.58
GMNN O75496 1/20 0.58
TP53 P04637 1/20 0.58
HSP90AA1 P07900 1/20 0.58
CYP2D6 P10635 1/20 0.58
MMP9 P14780 1/20 0.58
NFKB1 P19838 1/20 0.58
MMP8 P22894 1/20 0.58
THPO P40225 1/20 0.58
MTOR P42345 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxyquinoline SCHEMBL29460084 1.00 KDM4E (0.58) KDM4ELMNACCR1CCR5CCR8
Oxyquinoline SCHEMBL952769 0.95 KDM4E (0.58) KDM4ELMNACCR1CCR5CCR8
Oxyquinoline SCHEMBL22660883 0.95 KDM4E (0.58) KDM4ELMNACCR1CCR5CCR8
Oxyquinoline SCHEMBL3357860 0.95 KDM4E (0.58) KDM4ELMNACCR1CCR5CCR8
Oxyquinoline SCHEMBL23175212 0.95 KDM4E (0.58) KDM4ELMNACCR1CCR5CCR8
Oxyquinoline SCHEMBL23091400 0.95 KDM4E (0.58) KDM4ELMNACCR1CCR5CCR8
Oxyquinoline SCHEMBL296880 0.95 KDM4E (0.58) KDM4ELMNACCR1CCR5CCR8
Oxyquinoline SCHEMBL8537748 0.95 KDM4E (0.58) KDM4ELMNACCR1CCR5CCR8
Oxyquinoline SCHEMBL543361 0.95 KDM4E (0.58) KDM4ELMNACCR1CCR5CCR8
Oxyquinoline SCHEMBL2873348 0.95 KDM4E (0.58) KDM4ELMNACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 634 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3582778-B1 COMPOSITIONS OF GALLIUM (III) COMPLEXES FOR ORAL ADMINISTRATION MEDMELIOR INC (CA) 2022-10-05 EP claimed
US-11213530-B2 Gallium in the treatment of coronavirus disease BERNSTEIN LAWRENCE RICHARD (US) 2022-01-04 US claimed
WO-2021258086-A2 GALLIUM IN THE TREATENT OF CORONAVIRUS DISEASE BERNSTEIN LAWRENCE (US) 2021-12-23 WO claimed
US-20210275544-A1 Gallium in the treatment of coronavirus disease BERNSTEIN LAWRENCE RICHARD (US) 2021-09-09 US claimed
US-10933021-B2 Compositions of gallium (III) complexes for oral administration ALTUM PHARMACEUTICALS INC. (CA) 2021-03-02 US claimed
US-20200038334-A1 COMPOSITIONS OF GALLIUM (III) COMPLEXES FOR ORAL ADMINISTRATION ALTUM PHARMACEUTICALS INC. (CA) 2020-02-06 US claimed
US-10548849-B2 Compositions of gallium (III) complexes for oral administration ALTUM PHARMACEUTICALS INC. (CA) 2020-02-04 US claimed
US-20190262271-A1 A NANOCOMPLEX AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-08-29 US claimed
US-20190255100-A1 TREATMENT OF CARDIOVASCULAR DISEASE BY USING GALLIUM COMPOUNDS TO BIND CALCIFIED LESIONS LIPIDRISK, LLC 2019-08-22 US claimed
EP-2243177-B1 PHOSPHORESCENT OLED HAVING DOUBLE HOLE-BLOCKING LAYERS GLOBAL OLED TECHNOLOGY LLC (US) 2019-05-15 EP claimed
WO-2008036429-A1 GALLIUM COMPOSITIONS FOR THE TREATMENT OF LIVER CANCER AND METHODS OF USE BERNSTEIN LAWRENCE R (US) 2008-03-27 WO claimed
WO-2007100382-A2 ORALLY ADMINISTRABLE GALLIUM COMPOSITIONS AND METHOD OF USE BERNSTEIN LAWRENCE R (US) 2007-09-07 WO claimed
US-20070098815-A1 Orally Administrable Gallium Compositions and Methods of Use BERNSTEIN LAWRENCE R 2007-05-03 US claimed
EP-1694341-A1 USE OF GALLIUM TO TREAT INFLAMMATORY ARTHRITIS TITAN PHARMACEUTICALS, INC. (US) 2006-08-30 EP claimed
US-6967062-B2 White light-emitting OLED device having a blue light-emitting layer doped with an electron-transporting or a hole-transporting material or both EASTMAN KODAK COMPANY (US) 2005-11-22 US claimed
US-20050220895-A1 Use of gallium to treat inflammatory arthritis TITAN PHARMACEUTICALS, INC. 2005-10-06 US claimed
WO-2005058331-A1 USE OF GALLIUM TO TREAT INFLAMMATORY ARTHRITIS TITAN PHARMACEUTICALS, INC. (US) 2005-06-30 WO claimed
WO-2005033246-A1 GREEN ORGANIC LIGHT-EMITTING DIODES EASTMAN KODAK COMPANY (US) 2005-04-14 WO claimed
US-20050058853-A1 Green organic light-emitting diodes EASTMAN KODAK COMPANY 2005-03-17 US claimed
US-20040185300-A1 White light-emitting OLED device having a blue light-emitting layer doped with an electron-transporting or a hole-transporting material or both EASTMAN KODAK COMPANY 2004-09-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10548849-B2 Compositions of gallium (III) complexes for oral administration COG5, COG3, COG6 KDM4E 3992/4885LMNA 3709/4885CCR1 2082/4885
US-20200038334-A1 COMPOSITIONS OF GALLIUM (III) COMPLEXES FOR ORAL ADMINISTRATION COG5, COG3, COG6 KDM4E 3992/4885LMNA 3709/4885CCR1 2082/4885
US-10933021-B2 Compositions of gallium (III) complexes for oral administration COG5, COG3, COG6 KDM4E 3992/4885LMNA 3709/4885CCR1 2082/4885
US-20050220895-A1 Use of gallium to treat inflammatory arthritis MMP8, CD68, SYVN1 KDM4E 4707/4885LMNA 4408/4885CCR1 983/4885
US-20190262271-A1 A NANOCOMPLEX CD44, MUC1, PROC KDM4E 3626/4885LMNA 3210/4885CCR1 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.